Literature DB >> 16825430

MDM2 SNP309 accelerates colorectal tumour formation in women.

Gareth L Bond, Chiara Menin, Roberta Bertorelle, Pia Alhopuro, Lauri A Aaltonen, Arnold J Levine.   

Abstract

Recent studies have shown that the G-allele of MDM2 SNP309 (T/G) in the p53 tumour suppressor pathway can accelerate tumorigenesis and alter the risk of various cancers in women and not in men. In this report, data are presented from two independent groups of patients that suggest that the G-allele of SNP309 accelerates colorectal tumour formation only in women, and that lend further support to the model that primarily female-specific hormones, such as oestrogen, could either directly or indirectly allow for the G-allele of SNP309 to accelerate tumour formation in women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825430      PMCID: PMC2563203          DOI: 10.1136/jmg.2006.043539

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

Review 1.  MDM2 is a central node in the p53 pathway: 12 years and counting.

Authors:  Gareth L Bond; Wenwei Hu; Arnold J Levine
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

2.  The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.

Authors:  P Alhopuro; S K Ylisaukko-Oja; W J Koskinen; P Bono; J Arola; H J Järvinen; J-P Mecklin; T Atula; R Kontio; A A Mäkitie; S Suominen; I Leivo; P Vahteristo; L-M Aaltonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

3.  The IARC TP53 database: new online mutation analysis and recommendations to users.

Authors:  Magali Olivier; Ros Eeles; Monica Hollstein; Mohammed A Khan; Curtis C Harris; Pierre Hainaut
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

4.  The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  S Krüger; A Bier; C Engel; E Mangold; C Pagenstecher; M von Knebel Doeberitz; E Holinski-Feder; G Moeslein; K Schulmann; J Plaschke; J Rüschoff; H K Schackert
Journal:  J Med Genet       Date:  2005-10       Impact factor: 6.318

5.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors:  Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

6.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

Review 7.  Improving cancer therapy by non-genotoxic activation of p53.

Authors:  S Lain; D Lane
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

8.  p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population.

Authors:  J Shawn Jones; Xuedong Chi; Xiangjun Gu; Patrick M Lynch; Christopher I Amos; Marsha L Frazier
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

9.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.

Authors:  Helge Lind; Shanbeh Zienolddiny; Per Olav Ekstrøm; Vidar Skaug; Aage Haugen
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

10.  Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.

Authors:  Chiara Menin; Maria Chiara Scaini; Gian Luca De Salvo; Martina Biscuola; Monica Quaggio; Giovanni Esposito; Claudio Belluco; Marco Montagna; Simona Agata; Emma D'Andrea; Donato Nitti; Alberto Amadori; Roberta Bertorelle
Journal:  J Natl Cancer Inst       Date:  2006-02-15       Impact factor: 13.506

  10 in total
  47 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Transcription       Date:  2011 Sep-Oct

3.  Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.

Authors:  Qiang Fu; Guoqiang Zhang; Hongwei Chen; Youwei Zheng; Jing Cheng
Journal:  Tumour Biol       Date:  2013-08-03

4.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

Review 5.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  Cansu Karakas; Cassie Wang; Fangming Deng; Hongying Huang; Dongwen Wang; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

Review 6.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

8.  Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.

Authors:  Sajid A Khan; Kamran Idrees; Ann Forslund; Zhaoshi Zeng; Shoshana Rosenberg; Hanna Pincas; Francis Barany; Kenneth Offit; Michael P Laquaglia; Philip B Paty
Journal:  J Surg Oncol       Date:  2008-06-01       Impact factor: 3.454

9.  Germline mutations and polymorphisms in the origins of cancers in women.

Authors:  Kim M Hirshfield; Timothy R Rebbeck; Arnold J Levine
Journal:  J Oncol       Date:  2010-01-10       Impact factor: 4.375

10.  Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.

Authors:  Ying-Fang Sun; Jyh-Der Leu; Su-Mei Chen; I-Feng Lin; Yi-Jang Lee
Journal:  BMC Cancer       Date:  2009-01-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.